Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study
- PMID: 17362317
- DOI: 10.1111/j.1525-1438.2007.00794.x
Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study
Abstract
The FACT/GOG (Gynecologic Oncology Group) Neurotoxicity (Ntx) subscale for assessing platinum/paclitaxel-induced neurologic symptoms was evaluated. The 11-item questionnaire was administered to patients with advanced endometrial cancer treated with doxorubicin/cisplatin (AP) or doxorubicin/cisplatin/paclitaxel (TAP) prior to 1-7 cycles of treatment in GOG 177. The subscale was evaluated in 134 patients in the TAP group for internal reliability, construct validity, criteria validity, sensitivity to treatment differences, and change over time. Cronbach coefficients for internal consistency prior to cycles 1-7 were 0.85, 0.80, 0.84, 0.82, 0.82, 0.85, and 0.84, respectively. The area under the receiver operating characteristic curve was 0.81 for the Ntx score prior to cycle 3. The TAP arm Ntx scores increased significantly from 3.67 at baseline to 8.13 prior to cycle 7; these were higher than the AP arm Ntx scores, which increased from 3.54 at baseline to 4.72 prior to cycle 7. The four sensory items accounted for 80% of treatment differences and 63% of longitudinal changes in the observed subscale score. The 11-item Ntx subscale reliably and validly assesses platinum/paclitaxel-induced peripheral neuropathy. A reduced four-item version is an efficient alternative in measuring this toxicity in clinical trials without compromising its performance.
Similar articles
-
Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).Asia Pac J Clin Oncol. 2019 Feb;15(1):56-62. doi: 10.1111/ajco.13000. Epub 2018 Jun 5. Asia Pac J Clin Oncol. 2019. PMID: 29873180
-
Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.Health Qual Life Outcomes. 2020 Jul 23;18(1):246. doi: 10.1186/s12955-020-01493-y. Health Qual Life Outcomes. 2020. PMID: 32703223 Free PMC article.
-
A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.Support Care Cancer. 2013 Jul;21(7):1947-54. doi: 10.1007/s00520-013-1748-0. Epub 2013 Feb 19. Support Care Cancer. 2013. PMID: 23420555 Clinical Trial.
-
The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix.Semin Oncol. 1995 Oct;22(5 Suppl 12):67-75. Semin Oncol. 1995. PMID: 7481864 Review.
-
Medical therapy of advanced malignant epithelial tumours of the ovary.Forum (Genova). 2000 Oct-Dec;10(4):323-32. Forum (Genova). 2000. PMID: 11535983 Review.
Cited by
-
Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol. 2015 Feb;136(2):323-7. doi: 10.1016/j.ygyno.2014.12.021. Epub 2014 Dec 18. Gynecol Oncol. 2015. PMID: 25529832 Free PMC article. Clinical Trial.
-
Validation of the Patient Neurotoxicity Questionnaire for Patients Suffering From Chemotherapy-Induced Peripheral Neuropathy in Greek.Cureus. 2021 Apr 6;13(4):e14324. doi: 10.7759/cureus.14324. Cureus. 2021. PMID: 33842180 Free PMC article.
-
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).Lancet Oncol. 2015 Mar;16(3):301-11. doi: 10.1016/S1470-2045(15)70004-5. Epub 2015 Jan 29. Lancet Oncol. 2015. PMID: 25638326 Free PMC article. Clinical Trial.
-
Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations.Support Care Cancer. 2014 May;22(5):1161-9. doi: 10.1007/s00520-013-2068-0. Epub 2013 Dec 21. Support Care Cancer. 2014. PMID: 24362842 Free PMC article.
-
Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm phase II study (NAC-GA trial).Ann Gastroenterol Surg. 2023 Jul 8;7(6):997-1008. doi: 10.1002/ags3.12712. eCollection 2023 Nov. Ann Gastroenterol Surg. 2023. PMID: 37927936 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous